---
document_datetime: 2025-03-27 14:56:55
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/reagila-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: reagila-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0998372
conversion_datetime: 2025-12-24 08:04:10.262486
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Reagila

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0035              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 11/03/2025                          |                                             | SmPC and PL                      |           |
| X/0033               | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                             | 30/05/2024                          | 01/08/2024                                  | SmPC, Labelling and              |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034             | Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 11/04/2024 | 01/08/2024 | SmPC and PL | Please refer to Scientific Discussion Reagila- H/C/002770/II/0034. For more information, please refer to the Summary of Product Characteristics. Update of sections 4.3, 4.4 and 4.5 of the SmPC to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on results from a study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly. |
| PSUSA/10623 /202210 | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/05/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0032             | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28/03/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0031             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/03/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0027             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/06/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| N/0029      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                       | 02/06/2022   | 23/01/2023   | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0028/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site | 02/05/2022   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0026      | Renewal of the marketing authorisation.                                                                                                                                                                                                                | 27/01/2022   | 04/04/2022   | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Reagila in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity. |
| II/0023     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                      | 10/02/2022   | 23/01/2023   | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0020/G   | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging                                                                                                         | 16/12/2021   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site   |            |            |                        | site      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| II/0022   | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                 | 18/11/2021 | n/a        |                        |           |
| IB/0024/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside of the currently approved pack sizes                                                                                                                                   | 26/10/2021 | 04/04/2022 | SmPC, Labelling and PL | the range |

<div style=\"page-break-after: always\"></div>

| IB/0021/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary   | 13/10/2021   | n/a        |    |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------------------------------|
| IA/0025             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/09/2021   | n/a        |    |                                   |
| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/07/2021   | 04/04/2022 | PL |                                   |
| PSUSA/10623 /202010 | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/05/2021   | n/a        |    | PRAC Recommendation - maintenance |
| N/0016              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/10/2020   | 04/04/2022 | PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10623 /201910   | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                         | 17/04/2020   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| PSUSA/10623 /201904   | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                         | 31/10/2019   | n/a   | PRAC Recommendation - maintenance   |
| II/0010               | Submission of in vitro metabolism study report (R188-A15) and consequential update of the Risk Management Plan (version 1.7). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                       | 03/10/2019   | n/a   |                                     |
| IB/0014               | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                       | 19/09/2019   | n/a   |                                     |
| IB/0013               | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                    | 19/09/2019   | n/a   |                                     |
| IA/0011/G             | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - | 29/05/2019   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|                     | Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10623 /201810 | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/05/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| PSUSA/10623 /201804 | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/10/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| II/0008             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                                       | 13/09/2018 | n/a        |                        |                                   |
| PSUSA/10623 /201710 | Periodic Safety Update EU Single assessment - cariprazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/05/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0006              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/05/2018 | 12/12/2018 | PL                     |                                   |
| IB/0004/G           | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. | 18/12/2017 | 12/12/2018 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0001/G | This was an application for a group of variations.                                                                                                                                                                                                   | 15/09/2017 | n/a |